VX17-445-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal F

Project: Research project

Project Details

StatusFinished
Effective start/end date7/10/187/17/20

Funding

  • Vertex Pharmaceuticals Incorporated (VX17-445-102)